Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
May 26, 2022
Ryan Allway May 26th, 2022 News, Top News The Company received positive comments from the FDA to determine potential new clinical endpoints to support Emergency Use Authorization TORONTO, May 26, 2022 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty... Read more
Rapid Dose Therapeutics and McMaster University’s COVID-19 Vaccine Study Receives NSERC Research and Development Grant
Uncategorized December 22, 2021
Ryan Allway December 22nd, 2021 Uncategorized BURLINGTON, Ontario, December 22, 2021–(BUSINESS WIRE)–Today, Rapid Dose Therapeutics Corp. (“RDT” or the “Company“) (CSE: DOSE) and McMaster University (“McMaster“) are pleased to announce that the ongoing development of an orally delivered vaccine candidate for COVID-19 has received the final installment of the... Read more
Algernon Pharmaceuticals to File End-of-Phase 2 Meeting Request with U.S. FDA for Possible Ifenprodil Phase 3 COVID-19 Trial
April 8, 2021
Ryan Allway April 8th, 2021 Psychedelics VANCOUVER, British Columbia, April 08, 2021 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it plans to formalize discussions with the U.S. Food and... Read more
Students with prior drug convictions are no longer excluded from obtaining federal student aid under a recently approved congressional appropriation package. Although the main goal of this bill is to keep the government appropriately funded, with these unprecedented times we are facing because of COVID19, it creates challenges. Provisions strike a 1998 law, subsection of […]
The post Students with Drug Convictions can now Receive Federal Aid appeared first on The Cannifornian.
Read more
